iiinova — where your digital self keeps evolving

Susan Dent MD FRCPC @susandent.bsky.social · 19/05/2025

It is so important to understand how cancer treatments impact cardiovascular health!

Reposted by Susan Dent MD FRCPC

Jen L, PhD @drjkyl.bsky.social · 25/04/2025

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer - Apr 17, 2025 @journals.sagepub.com journals.sagepub.com/doi/10.1177/...

001

Reposted by Susan Dent MD FRCPC

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 16/04/2025

I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation

0101

Reposted by Susan Dent MD FRCPC

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · 15/04/2025

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer. 🔓 pubmed.ncbi.nlm.nih.gov/40196378/ @ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

056

Reposted by Susan Dent MD FRCPC

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/04/2025

In a multivariable analysis, omitting ET was associated w/⬆️ risk of death HR 1.23; For ER 1%-5% HR 1.16; For ER 6%-10% HR 1.42 Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

ascopubs.org

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer

PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%)...

0115

Susan Dent MD FRCPC @susandent.bsky.social · 18/03/2025

Congratulations to the University of Rochester for being named the 73rd NCI designated Cancer Center!!!!

021

Reposted by Susan Dent MD FRCPC

Robert S Miller MD @rsm2800.bsky.social · 18/03/2025

Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...

002

Susan Dent MD FRCPC @susandent.bsky.social · 08/03/2025

On International Women’s Day spending time with this amazing group of women who provide flying fishing retreats for breast cancer survivors!

020

Susan Dent MD FRCPC @susandent.bsky.social · 27/01/2025

Important to consider comorbidities when selecting first line therapy in HR+HER2- metastatic breast cancer !

030

Susan Dent MD FRCPC @susandent.bsky.social · 25/01/2025

Dear colleagues. We have an exciting opportunity for a breast cancer medical oncologist in Rochester New York! If you are interested in leading a dynamic clinical research program let me know. Come and join a growing team while enjoying the wonderful nature of upper state New York!

000

Reposted by Susan Dent MD FRCPC

Sarah Sammons MD @drsarahsammons.bsky.social · 19/01/2025

Interesting endpoint and trial. Few MBC patients treated and very small. For oligoprogressive cancer, SBRT could delay time to systemic therapy change. This could could valuable for the right patient trying to delay time to chemotherapy. www.redjournal.org/article/S036...

redjournal.org

The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial

In oligoprogressive (OP) cancer, there are a limited number of metastatic areas progressing on a background of stable or responding to widespread cancer. Although the standard of care for OP is changi...

1112

Reposted by Susan Dent MD FRCPC

Kristina Jankovic @kjankovic.bsky.social · 03/01/2025

🆕 #HELEN006 trial: weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects. A potential new standard for neoadjuvant therapy❓ @oncoalert.bsky.social thelancet.com/journals/lanon…

063

Reposted by Susan Dent MD FRCPC

Maryam Lustberg MD MPH FASCO @maryamlustberg.bsky.social · 30/12/2024

Happy new year to all

1111

Susan Dent MD FRCPC @susandent.bsky.social · 23/12/2024

77510762.flowpaper.com/ICOS2024News... Thanks to all of my cardio-oncology colleagues for another successful year! We have made tremendous progress in the treatment of cancer - let’s not forget about cardiovascular health. Looking forward to 2025 - Cute Cancer Save Herts!

77510762.flowpaper.com

IC-OS 2024 Newsletter

211

Reposted by Susan Dent MD FRCPC

Mother Jones @motherjones.com · 20/12/2024

3. Insurance profits outpace health care spending

Title: Insurance profits outpace health care spending
Subtitle: Increase in combined earnings of UnitedHealth Group, Evelance, and Cigna

Photo: A line graph that shows the increase in combined earnings of UnitedHealth Group, Elevance, and Cigna (shown as "Cumulative earnings") compared to the increase in national health care expenditures over time from 2012 to 2022. “Cumulative earnings” moves from 8.35% in 2012 to 261.56% in 2022. “National” moves from 4% in 2012 to 67% in 2022.

Chart credit: Michael Mechanic/Mother Jones. Source: Commonwealth Fund

11239102

Reposted by Susan Dent MD FRCPC

Darcy Burbage, DNP, RN, AOCN @darcyburbage.bsky.social · 19/12/2024

Survivorship means different things to different individuals. One of which remains how to best operationalize the guidance from nationally recognized organizations and clinical practice guidelines to ensure equitable & comprehensive care #oncsky #oncologynursing jnccn.org/view/journal...

jnccn.org

083

Reposted by Susan Dent MD FRCPC

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 19/12/2024

📣Abstract deadline for St. Gallen’s Breast Cancer Consensus Conf extended!! The top 5️⃣ posters present in front of global leaders. 🌍 [plus you’ll join me in beautiful Vienna 🇦🇹] Final deadline: Jan 5, 2025 🔗 sgbcc2025.abstractserver.com/submission/#... #oncsky #SGBCC2025 #bcsm @oncoalert.bsky.social

063

Reposted by Susan Dent MD FRCPC

Donna A Gaffney, DNSc, PMHCNS-BC, FAAN @donnagaffney.bsky.social · 19/12/2024

Bravo Kate! Thank you for your leadership and commitment to children everywhere.

0113

Reposted by Susan Dent MD FRCPC

Yukinori Ozaki @yukinoriozaki.bsky.social · 16/12/2024

Overview of #SABCS24! So many important trials presented. @oncoalert.bsky.social #breastcancer

042

Reposted by Susan Dent MD FRCPC

Yüksel Ürün @yukselurun.bsky.social · 16/12/2024

Prostate Cancer Therapy Cardiotoxicity Map: 💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC. #ProstateCancer #Oncology @oncoalert.bsky.social @oncbrothers.bsky.social

072

Reposted by Susan Dent MD FRCPC

Dana-Farber News @danafarbernews.bsky.social · 18/12/2024

Congratulations to Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, who has been elected 2026-27 @ascopost.bsky.social president. Dr. Mittendorf will be the seventh @danafarber.bsky.social-affiliated physician to serve as president since ASCO was founded in 1964. bit.ly/3VJ5TUQ

0145

Reposted by Susan Dent MD FRCPC

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · 13/12/2024

Y'all...Mike Danso isn't on social media. He said we may be able to convince him to join- give me some likes from #SABCS24!

2132

Reposted by Susan Dent MD FRCPC

Martha Carlson @marthacarlson.bsky.social · 11/12/2024

Big takeaway from 2 sessions Tuesday #SABCS24: “Dose reduction is a normal process” and dose optimization needs to be looked at early in clinical trials. 🗣️advocates Victoria Goldberg and Julia Maues who drove this home & talked abt Patient-Centered Dosing Initiative (therightdose.org) #Cansky #bcsm

Panel with Victoria Goldberg third from left

Julia Maues at the SABCS podium during session specifically about dose optimization

1126

Reposted by Susan Dent MD FRCPC

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/12/2024

ZEST—a ph3 trial for TNBC w/ ctDNA screening 🛑stopped early due to low randomization 🩻 50% with mets at time ctDNA+ ⏲️ ctDNA+ occurred often on 1st test/ ≤6 mos from EoT ▫️Recurrence-free interval longer w/ niraparib, but not powered for endpoint #SABCS24 @oncoalert.bsky.social

053

Reposted by Susan Dent MD FRCPC

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · 13/12/2024

Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review. First line CDK 2nd line profile driven ADC/chemo once endo-R! @sabcs.bsky.social #SABCS24 @oncoalert.bsky.social

0185

Reposted by Susan Dent MD FRCPC

Ilana Schlam @ilanaschlam.bsky.social · 13/12/2024

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @oncoalert.bsky.social

04619

Susan Dent MD FRCPC @susandent.bsky.social · 13/12/2024

Sequencing of ADCs a challenge in the real world setting. #sabcs2024

000

Reposted by Susan Dent MD FRCPC

Richard Simcock @breastdocuk.bsky.social · 13/12/2024

Ian Krop discussant on ctDNA in discussing the ZEST trial: No study has shown that intervening on a positive trst improves outcomes No study has shown that deescalating therapy on a negative test is safe For trial use only! #SABCS24

052

Reposted by Susan Dent MD FRCPC

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · 13/12/2024

Dr. Krop emphasizes we don't have the data in #bcsm that the GI literature does for MRD. 🛑 Should NOT order tests (outside of a clinical trial) without clear actions to take based on results ‼️ ❓Will outcomes be changed in ctDNA+? Unsure. #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social

1176

Susan Dent MD FRCPC @susandent.bsky.social · 13/12/2024

Anthracyclines still have a role in the treatment of those patients with early breast cancer at very high risk of disease recurrence!

063

Reposted by Susan Dent MD FRCPC

Sarah Sammons MD @drsarahsammons.bsky.social · 12/12/2024

Wow! Median PFS was 44.3 months for pts treated with IBRANCE in combination with HP and endocrine therapy, and 29.1 months (95% CI: 23.3-38.6) for patients treated with HP and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); p= 0.0074]. 44 month first-line PFS! @oncbrothers.bsky.social #SABCS

2226

Reposted by Susan Dent MD FRCPC

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/12/2024

Omission of Axillary surgery continues to build momentum Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org

nejm.org

Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial | NEJM

Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. In this prospective, randomized, noninferiority trial, we i...

1174

Susan Dent MD FRCPC @susandent.bsky.social · 12/12/2024

Thanks to those who stopped by for our International cardio-oncology society (ICOS) reception during the 2024 SABCS symposium #sabcs2024

010

Susan Dent MD FRCPC @susandent.bsky.social · 11/12/2024

ADCs offer so much promise for our patients but still need to understand; sequencing, biomarkers for response , toxicity management and drivers of resistance. #sabcs2024

020

Reposted by Susan Dent MD FRCPC

Sarah Sammons MD @drsarahsammons.bsky.social · 11/12/2024

Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.

0105

Reposted by Susan Dent MD FRCPC

Sarah Sammons MD @drsarahsammons.bsky.social · 11/12/2024

LeVee et al; Real world immune mediated toxicity (iTox) in >400 early stage breast cancer pts in multi-institutional study. Nearly 73% incidence of all grade iTox! 2x higher than reported in Keynote 522. Age >50 and CDK risk factors for iTox @oncbrothers.bsky.social #SABCS24

0166

Susan Dent MD FRCPC @susandent.bsky.social · 11/12/2024

So important to consider CV events in patients with cancer. Great session at SABCS2024 on ICI toxicity!

020

Susan Dent MD FRCPC @susandent.bsky.social · 01/12/2024

To all my ASCO colleagues please remember to vote! It is so important to make your voice heard.

000